Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: In vivo evaluation in KHT murine sarcomas
- Medical Research Council, Didcot, Oxon (England)
The efficacies of a series of potential prodrugs of RSU-1069 and its alkyl-aziridine analogues were assessed. These 1-(2-haloethylamino)-3-(2-nitro-1-imidazolyl)-2-propanol compounds were designed to cyclize in vivo to generate 2-nitro-imidazoles with aziridine (RSU-1069) or alkyl-substituted aziridine (RSU-1164, RB-7040, or RSU-1150) functions. Maximum tolerated single, intraperitoneal doses (MTD) were determined in C3H/He mice bearing subcutaneous KHT sarcomas, and a drug dose-response relationship for radiosensitization was established for each compound administered at the optimum time (45-60 min) before local irradiation of tumors with a 10-Gy dose of X-rays. The potentials of the compounds as bioreductive cytotoxins were studied by administering them immediately after irradiation. Tumor cell survival was measured 18-24 h after treatment in an in vitro soft agar clonogenic assay. Results of toxicity, radiosensitization, and bioreductive cytotoxicity assays for each of the prodrugs (RB-6171, RB-6172, RB-6173, RB-6174, and RB-6175) of the alkyl-substituted aziridines were entirely consistent with complete conversion to their respective target compounds. For example, RB-6171 (the prodrug form of RSU-1164) was only about four times less efficient than RSU-1069 as a radiosensitizer and bioreductive cytotoxin but had an MTD 7.5 times higher. In contrast, prodrugs of RSU-1069 (RB-6144 and RB-6145) were two- to threefold less toxic than their expected product. RB-6144 was a poor radiosensitizer and bioreductive agent compared with RSU-1069 and was similar to RB-6170, a nonalkylating nitroimidazole. This is consistent with the observation that there is limited conversion of RB-6144 to RSU-1069 in vitro. However, radiosensitization and bioreductive cytotoxicity produced by RB-6145 were only slightly less than the effects produced by RSU-1069.
- OSTI ID:
- 6167404
- Journal Information:
- Radiation Research; (USA), Vol. 124:1 Suppl; ISSN 0033-7587
- Country of Publication:
- United States
- Language:
- English
Similar Records
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice
Phosphate-group of DNA as a potential target for RSU-1069, a nitroimidazole-aziridine radiosensitizer
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
RADIOSENSITIZERS
TOXICITY
SARCOMAS
COMBINED THERAPY
ANTINEOPLASTIC DRUGS
DOSE-RESPONSE RELATIONSHIPS
EXPERIMENTAL NEOPLASMS
MICE
RADIATION DOSES
RADIOSENSITIVITY EFFECTS
X RADIATION
ANIMALS
DISEASES
DOSES
DRUGS
ELECTROMAGNETIC RADIATION
IONIZING RADIATIONS
MAMMALS
NEOPLASMS
RADIATIONS
RODENTS
THERAPY
VERTEBRATES
560152* - Radiation Effects on Animals- Animals
550603 - Medicine- External Radiation in Therapy- (1980-)